USPTO serial 77358724
ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS
Reviewed by CopyMark Law Group
Reg. 3484131Status 710
- Filing date
- Status date
- Registration date
- Aug 12, 2008
- Examiner
- THOMPSON, HEATHER
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jordan D. Glass
7-11 LEGION DR STE M-1CVALHALLA, NY 10595-2052UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Almond oil for pharmaceutical purposes; Almond oils for pharmaceutical purposes; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Astringents; Bismuth preparations for pharmaceutical purposes; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Gelatin capsules sold empty for pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of muscle soreness; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Ocular pharmaceuticals; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes,and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of hormone replacement; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely,appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Synthetic peptides for pharmaceutical purposes; Syringes sold filled with hormone replacement therapy; Unit dose capsules sold empty for pharmaceutical use; Vitamin and mineral preparations for use as ingredients in the food and pharmaceutical industry; Yeast or yeast extracts for medical, veterinary or pharmaceutical purposes | SECTION 8 - CANCELLED | Dec 1, 2007 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Thompson, Sharon G.
- Other trademarks owned by Thompson, Sharon G.
- Other trademarks owned by Thompson, Sharon G.
- Other trademarks in Class 005
- Similar marks named ANESIDORA'S JAR TAKING THE LID OFF ALL GOOD FORMULATIONS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 13, 2015 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Aug 12, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 27, 2008 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 7, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 21, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 9, 2008 | ALIE | ASSIGNED TO LIE | — |
| Mar 31, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 31, 2008 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 31, 2008 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 31, 2008 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 31, 2008 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 29, 2008 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 29, 2008 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 29, 2008 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 26, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 28, 2007 | NWAP | NEW APPLICATION ENTERED | — |